ARIAD Announces Commercial Distribution Agreement for Iclusig (ponatinib) in Turkey
May 06 2015 - 7:35AM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Gen Ilac, a
leading Turkish pharmaceutical company focused on the supply of
orphan drugs for the treatments of rare diseases, today announced
that ARIAD has granted Gen Ilac exclusive rights to distribute
Iclusig® (ponatinib) in Turkey for patients with
Philadelphia-positive leukemias.
Gen Ilac was granted the exclusive right to sell Iclusig as an
investigational product in Turkey on a named-patient basis and will
provide associated medical affairs and regulatory support. ARIAD
retains the option to file for marketing authorization at a later
date and, if approved, to hold the Marketing Authorization for
Iclusig in Turkey. Gen Ilac has the exclusive right then to market
and commercialize the product upon approval.
“This agreement with Gen Ilac furthers our mission to provide
Iclusig to patients in geographies beyond our core commercial
footprint,” said Marty J. Duvall, executive vice president and
chief commercial officer of ARIAD. “We are excited by Gen Ilac’s
experience and proven capabilities in this area, which makes them
an ideal partner to introduce Iclusig to patients and physicians in
Turkey.”
“We are excited by our partnership with ARIAD and the hope it
provides to refractory CML patients in Turkey,” said Abidin Gulmus,
chief executive officer of GEN ILAC. “This partnership aligns well
with our company mission and our expertise in providing treatments
in the field of hematology.”
About Iclusig® (ponatinib)
Iclusig is a kinase inhibitor. The primary target for Iclusig is
BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic
myeloid leukemia (CML) and Philadelphia-chromosome positive acute
lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using
ARIAD’s computational and structure-based drug design platform
specifically to inhibit the activity of BCR-ABL. Iclusig targets
not only native BCR-ABL but also its isoforms that carry mutations
that confer resistance to treatment, including the T315I mutation,
which has been associated with resistance to other approved
TKIs.
About Gen Ilac
GEN ILAC A.C, is a leading specialty pharmaceutical company
headquartered in Ankara, Turkey. Gen Ilac represents innovative
pharmaceutical and biotechnology companies, serving the medical
community and patients in specific therapeutic areas of neurology,
oncology, hematology and endocrinology. Gen Ilac has long-term
collaborations with a number of international companies, including
Biogen, Ipsen, PTC, Orphan Europe and others. Gen Ilac is taking a
leading role in Turkey bringing novel treatment options to patients
with difficult-to-treat or rare conditions.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter
(@ARIADPharm).
Iclusig® is a registered trademark of ARIAD
Pharmaceuticals, Inc. in the U.S. and is trademarked in Turkey.
Forward-Looking Statements
This press release contains forward-looking statements, each of
which are qualified in their entirety by this cautionary statement.
Any statements contained herein which do not describe historical
facts, including, but not limited to, statements regarding: our
mission to provide access to Iclusig in geographies outside of our
core commercial footprint; our partnership with Gen Ilac; and the
therapeutic potential of Iclusig, are forward-looking statements
that are based on management's expectations and are subject to
certain factors, risks and uncertainties that may cause actual
results, outcome of events, timing and performance to differ
materially from those expressed or implied by such statements.
These factors, risks and uncertainties include, but are not limited
to ARIAD’s ability to manufacture and supply Iclusig to Gen Ilac;
the ability of Gen Ilac to perform the contracted services; our
ability to obtain regulatory, pricing and reimbursement approval
for Iclusig in Turkey, including as a result of regulatory
developments and the level of any such pricing and reimbursement
approvals; safety issues related to Iclusig; Gen Ilac’s ability to
successfully distribute, market, promote and sell Iclusig in
Turkey; the timing and scope of any marketing authorization for
Iclusig in Turkey; third-party reimbursement; the timing and
success of sales of Iclusig in Turkey; the costs associated with
ARIAD’s development and manufacturing, commercial and other
activities; the adequacy of our capital resources and the
availability of additional funding; and those additional factors
detailed in ARIAD’s public filings with the U.S. Securities and
Exchange Commission, including our most recent Annual Report on
Form 10-K and subsequent Quarterly Reports on Form 10-Q. Except as
otherwise noted, these forward-looking statements speak only as of
the date of this press release and we undertake no obligation to
update or revise any of these statements to reflect events or
circumstances occurring after this press release. We caution
investors not to place considerable reliance on the forward-looking
statements contained in this press release.
For ARIAD InvestorsKendra Adams,
617-503-7028Kendra.adams@ariad.comorFor ARIAD MediaLiza
Heapes, 617-621-2315Liza.heapes@ariad.comorFor Gen
IlacAbidin Gulmus, +90 312 219 62 19gulmus.a@genilac.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Sep 2023 to Sep 2024